3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
3
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Melanoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Solid Malignancies
1
Small Cell Lung Carcinoma
1
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
1
Ovarian Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Kidney Neoplasms
1
Kidney Diseases
1
Gliosarcoma
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Oxaliplatin
31
Fluorouracil
31
Leucovorin
29
Irinotecan
23
Cetuximab
20
Bevacizumab
16
Capecitabine
13
Gemcitabine
11
pembrolizumab
8
Folfox protocol
7
Cisplatin
7
Carboplatin
7
Paclitaxel
6
Nivolumab
6
Cyclophosphamide
6
trifluridine tipiracil drug combination
5
cediranib
5
Erlotinib Hydrochloride
5
adagrasib
4
Ipilimumab
4
IFL protocol
4
Floxuridine
4
Bortezomib
4
veliparib
3
trametinib
3
sargramostim
3
poly ICLC
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colonic Neoplasms
×
Axitinib
×
Clear all
NCT04873895
2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1
Terminated
5 enrolled